Skip to content

Revolutionizing the future of targeted immune therapeutics

Our Approach
Our Team

Revolutionizing the future of targeted immune therapeutics

Transforming the lives of patients with immune disease through discovery and development of targeted biotherapeutics that rebalance the immune system


Q32 Bio is an experienced and high-performing team of industry professionals including talented scientists, immunologists, and drug developers empowered to deliver on OUR mission.

Currently, Q32 Bio has two clinical stage, investigational products being evaluated in clinical trials:

Our Pipeline
ADX-097
Innate System Modulator

ADX-097 is a tissue-targeted complement inhibitor, which is currently being evaluated in a Phase 1, first-in-human study. The objectives of the study are safety and proof of mechanism. The study is due to be completed in the first half of 2023.

ADX-914
Adaptive System Modulator

ADX-914 is an IL-7 Receptor α-targeted inhibitor, being evaluated in a Phase 2 study of patients with atopic dermatitis.